Our clinical trials

A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non-central Nervous System Tumors That are Amenable to Direct Injection.

A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors.

A Study to Test the Safety of the Investigational Drug Loxo-195 in Children and Adults That May Treat Cancer

Phase I/II, open-label, multicentre study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in paediatric patients with advanced solid tumours, haematological malignancies including lymphoma and acute leukaemias

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (E7080-G000-231)

TEMOkids Study: A Population Pharmacokinetic, Acceptability and Safety Study for KIMOZO, a Paediatric Oral Suspension of Temozolomide

Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors (PROVIN)

Molecular and Immunological Characterisation of high risk CHildhood Cancer At DiagnOsis, treatment and follow-up - Biological evaluation in children, adolescents and young adults.

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors.

Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma